MA-PERKINELMER
11.5.2020 15:02:06 CEST | Business Wire | Press release
PerkinElmer, Inc. , a global leader committed to innovating for a healthier world, today announced its Solus One™ Salmonella assay and methods have been granted First Action Official Methods of Analysis℠ (OMA) status, number 2020.03, from AOAC INTERNATIONAL (Association of Official Analytical Collaboration).
The Solus One Salmonella assay, which previously received ISO 16140 and AOAC Performance Tested Methods℠ (PTM) certification, detects Salmonella in select foods, with negative/presumptive positive results available in approximately 2 hours, post enrichment. Positive confirmation is then possible with an additional 24 hours. The assay can be run manually or with automation by adding Dynex Technologies’ DS-2® system.
Achieving OMA, the highest level of AOAC certification, involved a rigorous certification process that included simultaneous testing at over a dozen labs across the US, UK and South Africa. Data was then closely reviewed by an expert panel confirming result accuracy and repeatability of the Solus One Salmonella assay for a range of samples including raw salmon, romaine lettuce, cheddar cheese, instant non-fat dry milk, pasteurized liquid eggs, raw beef trim, cocoa, and herbs and spices. Tested food sample sizes ranged from 25g to 375g and swabs and sponges for production environment testing were also included.
“The World Health Organization estimates that Salmonella causes over 17 million people to become ill each year globally,” said Greg Sears, vice president and general manager, Food, PerkinElmer. “Members of the food industry, regulatory and research ecosystem around the world need to be able to depend on pathogen testing options that are reliable, consistent and efficient. We are pleased that our Solus One Salmonella assay and methods -- which have already been helping with food safety and quality globally -- have now achieved the highest level of AOAC certification.”
PerkinElmer’s pathogen assay offerings also include Solus One for Listeria and E. coli O157 and are part of the company’s broad food safety and quality solutions portfolio spanning across instruments, software, testing kits, reagents and services for grain, dairy, meats, produce, edible oils, seafood, herbs and spices and more. For more information please visit www.perkinelmer.com/category/food-safety-quality .
About PerkinElmer
PerkinElmer enables scientists, researchers and clinicians to address their most critical challenges across science and healthcare. With a mission focused on innovating for a healthier world, we deliver unique solutions to serve the diagnostics, life sciences, food and applied markets. We strategically partner with customers to enable earlier and more accurate insights supported by deep market knowledge and technical expertise. Our dedicated team of about 13,000 employees worldwide is passionate about helping customers work to create healthier families, improve the quality of life, and sustain the wellbeing and longevity of people globally. The Company reported revenue of approximately $2.9 billion in 2019, serves customers in 190 countries, and is a component of the S&P 500 index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200511005016/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Dream Accelerates Growth of Asset Management Platform With Acquisition of Chancerygate, a Leading U.K.-Based Industrial Asset Manager and Developer31.7.2026 00:09:00 CEST | Press release
Combined platform is one of Europe’s leaders in urban industrial with over 80 professionals and 27 million square feet of GLA managed or under development across nine countries. Dream Unlimited Corp. (“Dream”) (TSX: DRM) today announced that Dream and Dream Industrial Real Estate Investment Trust (“Dream Industrial REIT”) (TSX: DIR.UN), have entered into definitive agreements for Dream to acquire Chancerygate Limited (“Chancerygate” or “CG”), a U.K.-based industrial developer and asset manager with a 30-year track record in the multi-let industrial (“MLI”) sector. Chancerygate currently manages a diversified portfolio of income producing and development assets totaling £1.2 billion ($2.2 billion). As part of the transaction, Dream will assume Chancerygate's investment management and development platform. Dream Industrial REIT will acquire Chancerygate's wholly owned real estate assets and co-investment interests across its managed ventures for consideration of approximately £78 million
Dream Industrial REIT Announces Entry Into U.K. Multi-Let Industrial Market and Growth of Strategic Private Ventures in Europe31.7.2026 00:06:00 CEST | Press release
This press release contains forward-looking information that is based upon assumptions and is subject to risks and uncertainties as indicated in the cautionary note contained within this press release. All dollar amounts are in Canadian dollars unless otherwise indicated. Dream Industrial Real Estate Investment Trust (TSX: DIR.UN) (the “Trust” or the “REIT” or “DIR”) today announced that the Trust and Dream Unlimited Corp. (TSX: DRM) (“Dream”), have entered into definitive agreements for Dream to acquire Chancerygate Limited (“Chancerygate” or “CG”), a U.K.-based industrial developer and asset manager with a 30-year track record in the multi-let industrial (“MLI”) sector. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260730297448/en/ Audio Park, Sussex, UK - 104,000 sq ft As part of the transaction, Dream will assume Chancerygate's investment management and development platform. Dream Industrial REIT will acquire Chanceryga
Rimini Street Announces Fiscal Second Quarter 2026 Financial and Operating Results30.7.2026 22:03:00 CEST | Press release
Second Quarter Financial Highlights Include: Revenue of $111.1 million, up 6.7% year over year Adjusted Revenue of $108.0 million, up 10.0% year over year Remaining Performance Obligations (RPO) of $636.9 million, up 8.0% year over year Adjusted Annualized Recurring Revenue of $401.1 million, up 8.1% year over year Rimini Street, Inc., (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, managed services and Agentic AI ERP innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced results for the fiscal second quarter ended June 30, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260730702735/en/ Rimini Street Announces Fiscal Second Quarter 2026 Financial and Operating Results “Second-quarter results and four consecutive quarters of improved growth metrics demonstrate strong demand for our core Rimini Support™ offering, increasing adop
Rimini Street Launches Rimini Govern™ for AI to Deliver Comprehensive AI Agent Governance, Security & Interoperability as a Service30.7.2026 22:01:00 CEST | Press release
The new service enables organizations to quickly and easily implement and operationalize a global, enterprise-wide governance, control, security and performance measurement solution for AI agent activity and workflows Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced the immediate availability of Rimini Govern™ for AI, the newest offering in the company’s Rimini Govern portfolio of Governance, Risk and Compliance (GRC) solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260730389723/en/ Rimini Street Launches Rimini Govern™ for AI to Deliver Comprehensive AI Agent Governance, Security & Interoperability as a Service The new managed service is delivered 24/7/365 through Rimini Street’s Global Command Centers by expert AI engineers to help organizations: Accelerate AI agent deployment Reduc
One Biosciences Announces Data Validating New Method for Single-Cell Transcriptomic Tumor Profiling from Clinical Pathology Samples30.7.2026 21:03:00 CEST | Press release
Sample-to-report workflow generating single-cell RNA expression profiles using routine FFPE pathology slides from four institutions validated across 88 specimens and six cancer types One Biosciences, a techbio company pioneering clinical-grade single-cell tumor profiling, today announced data establishing that single-cell RNA expression profiles can be generated from the standard, formalin-fixed paraffin-embedded (FFPE) pathology specimens obtained in routine cancer care using the company’s proprietary platform, OneMap™. The study, conducted with collaborators at Centre Léon Bérard, Hôpital Bichat–Claude Bernard, Institut Curie, and Memorial Sloan Kettering Cancer Center, was released as a preprint on BiorXiv. “Every tumor is a unique ecosystem of many different types of cells, some cancerous, some not. Single cell profiling enables us to understand what those cells are, what they’re doing and potentially how that may impact treatment outcomes,” said Helena Yu, MD, thoracic medical onc
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
